Streamlining Phase 3 Fibromyalgia and Phase 2 Chronic Migraine Trials by Eliminating Interim Analyses Topline Results Expected for Both Programs…
More booster shots and improved ventilation remain part of the answer to decrease COVID-19 casesOTTAWA, April 13, 2023 (GLOBE NEWSWIRE)…
CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular…
IRVINE, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser…
Long COVID remains a high unmet need causing a myriad of complications for patients and costing the U.S. healthcare system…
BEDFORD, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early…
CRANSTON, R.I., April 12, 2023 (GLOBE NEWSWIRE) -- If you’ve ever had braces to create a beautiful smile, you’ll know…
NCPDP’s robust prescriber database, HCIdea, is now powered by H1’s trusted provider data to help NCPDP members reduce costs and…
Hariri, Celularity’s CEO, Chairman and Founder, will open the meeting with the keynote address highlighting recent progress and important next…
– 2022 marks Ceapro’s best performance in Company history with record sales of $18,800,000 compared to $17,200,000 for 2021, representing…